Lonza Group AG stock faces pressure amid Swiss trade data and transformation completion

PharmaVoiceAs M&A rebounds, here’s how pharmas can prepare to seal a deal

FierceBiotechKardigan buttons up $400M upsized IPO to power heart drugs toward phase 3

FierceBiotechNovocure device fails to improve brain cancer patients’ survival in phase 3 test

FierceBiotechNortiva purrs into action with long-acting Lynx platform salvaged from Langer startup

Endpoints NewsInnoviva revives Lyndra's long-acting oral drug platform

FierceBiotechBiogen inks $1B RayThera buyout to bag preclinical immunology assets

Endpoints NewsModerna adds commercial chief, expands Stephen Hoge's role; Reunion Neuroscience CEO departs

Endpoints NewsEli Lilly's TuneLab hits 100 members, adding Chai's AI models

CellChloroplast sunscreening by protein condensates confers high-light tolerance

PharmaVoiceA new Westlake-backed biotech takes aim at migraines

FierceBiotechF2G, Shionogi prep regulatory push after novel antifungal passes ph. 3 test

Endpoints NewsAntifungal from F2G, Shionogi succeeds in Phase 3 study